Literature DB >> 10100011

Fluctuations in CA 125 and CA 15-3 serum concentrations during spontaneous ovulatory cycles.

G G Bon1, P Kenemans, J J Dekker, P G Hompes, R A Verstraeten, G J van Kamp, J Schoemaker.   

Abstract

The aim of this study was to investigate cycle dependent changes of serum CA 125 and CA 15-3 concentrations during spontaneous ovulatory cycles. Twenty apparently healthy women with spontaneous menstrual cycles attending our infertility clinic were included. Of these women, 18 had occluded tubes as a result of sterilization. Ovulation was confirmed by luteinizing hormone test and ultrasonography and, to exclude endometriosis, a laparoscopy was performed. Serum samples for CA 125, CA 15-3, 17 beta-oestradiol and progesterone determinations were taken every second day starting on the 2nd day of the cycle until the 7th day of the next cycle. After correction for inter-individual variation in serum concentrations, highest CA 125 concentrations were found during the menstruation. During the follicular and peri-ovulatory phase CA 125 serum concentrations were lowest. For CA 15-3, serum concentrations were not statistically different throughout the cycle. CA 125 and oestradiol concentrations were negatively correlated, CA 15-3 and oestradiol concentrations were positively correlated. Absolute serum concentrations of both CA 125 and CA 15-3 vary among females. Within the female, fluctuations of CA 125 are phase related. In the population studied most of the patients had tubal obstruction and high CA 125 serum concentrations during menstruation, which revokes the theory that the menstrual rise of CA 125 is due only to retrograde menstruation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10100011     DOI: 10.1093/humrep/14.2.566

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  9 in total

1.  CA125 in ovarian cancer.

Authors:  Nathalie Scholler; Nicole Urban
Journal:  Biomark Med       Date:  2007-12       Impact factor: 2.851

2.  Chronic Medical Conditions and CA125 Levels among Women without Ovarian Cancer.

Authors:  Babatunde O Akinwunmi; Ana Babic; Allison F Vitonis; Daniel W Cramer; Linda Titus; Shelley S Tworoger; Kathryn L Terry
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-09-20       Impact factor: 4.254

3.  Predicting Circulating CA125 Levels among Healthy Premenopausal Women.

Authors:  Naoko Sasamoto; Ana Babic; Bernard A Rosner; Renée T Fortner; Allison F Vitonis; Hidemi Yamamoto; Raina N Fichorova; Anne Tjønneland; Louise Hansen; Kim Overvad; Marina Kvaskoff; Agnès Fournier; Francesca Romana Mancini; Heiner Boeing; Antonia Trichopoulou; Eleni Peppa; Anna Karakatsani; Domenico Palli; Valeria Pala; Amalia Mattiello; Rosario Tumino; Chiara C Grasso; N Charlotte Onland-Moret; Elisabete Weiderpass; J Ramón Quirós; Leila Lujan-Barroso; Miguel Rodríguez-Barranco; Sandra Colorado-Yohar; Aurelio Barricarte; Miren Dorronsoro; Annika Idahl; Eva Lundin; Hanna Sartor; Kay-Tee Khaw; Timothy J Key; David Muller; Elio Riboli; Marc J Gunter; Laure Dossus; Rudolf Kaaks; Daniel W Cramer; Shelley S Tworoger; Kathryn L Terry
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-04-04       Impact factor: 4.254

4.  Rhizoctonia bataticola lectin induces apoptosis and inhibits metastasis in ovarian cancer cells by interacting with CA 125 antigen differentially expressed on ovarian cells.

Authors:  Prajna Hegde; Sindhura B R; Suhas Ballal; Bale M Swamy; Shashikala R Inamdar
Journal:  Glycoconj J       Date:  2021-11-08       Impact factor: 2.916

5.  Ovarian tumor marker HE4 is differently expressed during the phases of the menstrual cycle in healthy young women.

Authors:  Emanuela Anastasi; Teresa Granato; Giulia Giovanna Marchei; Valentina Viggiani; Barbara Colaprisca; Sara Comploj; Maria Gabriella Reale; Luigi Frati; Cecilia Midulla
Journal:  Tumour Biol       Date:  2010-05-20

6.  How to Use CA-125 More Effectively in the Diagnosis of Deep Endometriosis.

Authors:  Marco Aurelio Pinho Oliveira; Thiers Soares Raymundo; Leila Cristina Soares; Thiago Rodrigues Dantas Pereira; Alessandra Viviane Evangelista Demôro
Journal:  Biomed Res Int       Date:  2017-06-04       Impact factor: 3.411

7.  Polymorphisms of MUC16 (CA125) and MUC1 (CA15.3) in relation to ovarian cancer risk and survival.

Authors:  Kristina A Williams; Kathryn L Terry; Shelley S Tworoger; Allison F Vitonis; Linda J Titus; Daniel W Cramer
Journal:  PLoS One       Date:  2014-02-13       Impact factor: 3.240

Review 8.  Developing a deeper insight into reproductive biomarkers.

Authors:  Braira Wahid; Hamid Bashir; Muhammad Bilal; Khansa Wahid; Aleena Sumrin
Journal:  Clin Exp Reprod Med       Date:  2017-12-31

9.  Glucose restriction combined with chemotherapy decreases telomere length and cancer antigen-125 secretion in ovarian carcinoma.

Authors:  Stephanie Antoun; David Atallah; Roula Tahtouh; Mona Diab Assaf; Malak Moubarak; Eliane Nasser Ayoub; Georges Chahine; George Hilal
Journal:  Oncol Lett       Date:  2019-12-20       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.